Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Novo Nordisk Reveals Tresiba US Pricing Premium To Levemir

This article was originally published in Scrip

Executive Summary

Novo Nordisk AS says its ultra-long-acting insulin Tresiba will be launched in the US at a 10% premium to the Danish company's currently marketed Levemir (insulin detemir) and made available first to specialists and pharmacies there in the fourth quarter, with full commercial launch slated for the first quarter of 2016.



Related Companies